Executive Summary
This digest of 11 new federal contracts, totaling $1.87 billion, reveals a civilian-agency-dominated landscape (9 of 11 contracts) with NASA as the standout spender, accounting for $1.08 billion (58%) of total obligations.
The highest-conviction signal is Northrop Grumman's $569.5 million firm-fixed-price delivery order for the JPSS-2 spacecraft, a long-duration (13-year) NASA/NOAA polar satellite program that reinforces its competitive moat in large space systems. Key risks include execution pressure on fixed-price contracts for complex space vehicles and the absence of defense-related awards from the DoD, which limits near-term defense sector exposure. Investors should watch NASA's budget trajectory for Earth science and space R&D, as well as option exercises on the RTX and Venatorx contracts.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior New Federal Contractors digest from May 19, 2026.
Investment Signals (3)
- Northrop Grumman's $569.5M NASA JPSS-2 Contract Bolsters Space Systems Backlog (HIGH)▲
Northrop Grumman secured a $569.5M firm-fixed-price delivery order for the JPSS-2 spacecraft, with performance through April 2028 and options totaling $606.7M. This full-and-open competition win reinforces its competitive moat in large space systems and provides a stable $43.8M annual revenue stream.
- RTX Corp's $200M NASA Landis Instrument Contract Signals Stable Science R&D Revenue (MEDIUM)▲
RTX Corp (Raytheon) won a $200M cost-plus-award-fee contract for three Landis flight instruments, with potential value up to $506.7M through 2037. The cost-plus structure reduces profit risk, and the full-and-open competition win demonstrates competitive strength in specialized aerospace R&D.
- Venatorx Pharmaceuticals' $72.1M BARDA Contract for Antibiotic R&D Has High Option Upside (MEDIUM)▲
Venatorx received a $72.1M cost-plus-fixed-fee BARDA contract for an antibiotic targeting antimicrobial resistance and biothreat pathogens, with options potentially increasing total value to $318.6M through 2032. The full-and-open competition and cost-plus structure reduce risk, while the long performance period offers sustained revenue potential.
Risk Flags (4)
- Execution [HIGH RISK]▼
Northrop Grumman's $569.5M firm-fixed-price contract for the JPSS-2 spacecraft carries medium execution risk due to the fixed-price nature on a complex space vehicle program. Any cost overruns or schedule delays could compress margins.
- Concentration [MEDIUM RISK]▼
NASA accounts for 58% ($1.08B) of total contract value across 4 awards, creating significant exposure to a single agency's budget trajectory. Any NASA budget cuts or program reprioritization could impact Northrop Grumman, RTX, and Caltech contracts.
- Budget [MEDIUM RISK]▼
The Magellan Federal $151.7M DOI contract for personal financial counselors is a non-core support function that may face budget scrutiny versus defense priorities, especially under a continuing resolution.
- Competition [MEDIUM RISK]▼
Leidos' $98.8M DHS/CBP contract for non-intrusive inspection systems faces potential re-compete risk as the contract nears its 2027 end date, with options extending to 2033. Subaward concentration (22% of total) introduces execution risk.
Opportunities (3)
- ◆
Northrop Grumman's JPSS-2 win positions it for follow-on NASA/NOAA polar satellite contracts, a stable-to-growing sector with increasing government investment. The $37.2M in options provides near-term upside.
- ◆
RTX Corp's $200M Landis contract has options valued up to $506.7M through 2037, offering significant long-term revenue growth in NASA Earth science programs. The cost-plus structure provides stable margins.
- ◆
Venatorx Pharmaceuticals' $72.1M BARDA contract for AMR antibiotics has options up to $318.6M, reflecting growing government investment in biodefense and antimicrobial resistance. Clinical milestones could trigger additional funding.
Sector Themes (3)
- ◆
NASA awarded 4 contracts totaling $1.08B (58% of total), spanning spacecraft manufacturing (Northrop Grumman), space R&D (Caltech), and Earth science instruments (RTX). This signals sustained government investment in space infrastructure and science missions.
- ◆
Four contracts totaling $388.7M (21% of total) were awarded by civilian agencies (DOI, DHS, HHS, CMS) for IT services, financial counseling, and inspection systems. These contracts provide stable, medium-term revenue but lack the growth catalysts of defense or space programs.
- ◆
Two HHS/BARDA contracts totaling $134.8M (7% of total) for antibiotic and biotechnology R&D highlight growing government commitment to antimicrobial resistance and pandemic preparedness. The cost-plus structures reduce contractor risk.
Watch List (5)
- 👁
{"entity"=>"Northrop Grumman (NOC)", "reason"=>"JPSS-2 contract execution risk and option exercise potential", "trigger"=>"JPSS-2 delivery milestones; $37.2M option exercise announcement"}
- 👁
{"entity"=>"RTX Corp (RTX)", "reason"=>"Landis instrument contract option exercise and NASA Earth science budget", "trigger"=>"NASA FY2027 budget request; Landis option exercise"}
- 👁
{"entity"=>"Venatorx Pharmaceuticals (private)", "reason"=>"BARDA contract option exercise and clinical milestones", "trigger"=>"Clinical trial results; BARDA option exercise announcement"}
- 👁
{"entity"=>"Leidos (LDOS)", "reason"=>"DHS/CBP contract re-compete risk near 2027", "trigger"=>"DHS border security technology budget; re-compete solicitation"}
- 👁
{"entity"=>"NASA Budget", "reason"=>"58% contract concentration creates systemic risk", "trigger"=>"FY2027 budget request; CR impact on NASA programs"}
Get daily alerts with 3 investment signals, 4 risk alerts, 3 opportunities and full AI analysis of all 11 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: New Federal Contractors
🇺🇸 More from United States
View all →May 28, 2026
US Pre-Market SEC Filings Roundup — May 28, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals